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Abstract The aim of this study is to investigate the preva-
lence of potential drug-drug interactions (PDDIs), as well as
classifying them in relation to level of severity, scientific ev-
idence, time of onset, and potential clinical impact in adult and
older adult patients with diabetes mellitus 2 (DM2). This
cross-sectional study was conducted in a tertiary care outpa-
tient center. The consecutive sample was made up of 140
patients with DM2. The Anatomical-Therapeutic-Chemical
Classification was used for classifying the classes of medica-
tions. The PDDIs were analyzed using the DRUG-REAX®
system. The relationships between PDDI and the associated
factors were ascertained using a multiple logistic regression
model. The prevalence of total PDDI was 75 %, and the prev-
alence of major severity PDDI was 20.7 %. Simvastatin
(30.8 %), captopril/enalapril (12.8 %), and oral anti-dia-
betics/insulin (12.8 %) were the medications which were most
involved in the major PDDI, bringing relevant potential clin-
ical impacts such as rhabdomyolysis, hyperkalemia, and im-
portant glycemic alterations. Polypharmacy was associated
with PDDI (adjusted odds ratio = 10.46, 95 % confidence
interval = 4.10–26.71). Diabetics were highly exposed to clin-
ically significant PDDI. It is important that health profes-
sionals should be aware of the risks related to PDDI, so that
measures may be implemented in order to assure safe care for
the patient.
Keywords Diabetesmellitus . Type 2 diabetes . Drug
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Introduction
Chronic non-communicable diseases (NCDs) currently repre-
sent an important public health problem with high morbidity
and mortality and significant economic repercussions. Al-
though NCDs do not occur exclusively in older adults, it is
anticipated that, with age, the individual will come to present
some morbidity [1, 2]. Among these, one finds diabetes
mellitus (DM), which, due to its chronic nature, requires
long-term management. As a result, the treatment of DM aims
to maintain good glycemic control, which generally prevents
the appearance of the chronic complications which make up
the principal causes of mortality, morbidity, and worsening of
quality of life [3, 4].
As the disease progresses and with the presence of comor-
bidities such as dyslipidemia and systemic arterial hyperten-
sion (SAH), the patient may come to use complex antidiabetic
treatments made up of three or more medications, as well as
making use of other therapeutic agents for treating other co-
morbidities [5, 6]. Through this, the individual has greater
exposure to the use of polypharmacy, that is, the use of five
or more medications, contributing to the occurrence of drug
interactions (DDIs) [7–9].
Drug interactions occur when two or more medications are
used concomitantly and the actions of one medication (object,
substrate) are altered by the presence of another (precipitant,
interacting medication), causing an alteration of the clinical or
pharmacological effect on the patient’s response to the treat-
ment [10, 11]. The present study considers the potential drug-
drug interactions (PDDIs). This term refers to the possibility
of a given medication altering the intensity of the
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pharmacological effect of another medication used simulta-
neously by the patient [10–12].
Studies in different scenarios have indicated negative out-
comes related to DDI, which can result in adverse events, a
reduction or increase in the medications’ therapeutic effects, an
increase in the toxicity of medications, an increase in the health
services’ costs, failure of the treatment, and/or serious complica-
tions for the patient, including the risk of death [8, 9, 12–18].
One study undertaken in Nepal [19] with adult and older
adult diabetic patients attended in tertiary healthcare identified
a prevalence of PDDI of 52.5 %, of which 92.1 % were of
moderate severity. The medications which contributed most
to the risk of PDDI were those acting on the cardiovascular
system (49.5 %), followed by oral antidiabetics (31.2 %). A
study undertaken with diabetic and hypertensive older adults
indicated a prevalence of 47.8 % of PDDI, with 93.2 % classi-
fied as moderate severity and 6.5 % as major. The medications
which contributed most to PDDI in this scenario were
acetylsalicylic acid (14.3 %), enalapril (12.6 %), glibenclamide
(12.0 %), and digoxin (8.6 %) [15].
However, other studies directed towards evaluating the
prevalence of PDDI, as well as its possible significant clinical
implications in diabetic adult and older adult individuals, are
scarce. In light of these considerations, this study aimed to
investigate the prevalence of potential PDDIs, as well as clas-
sifying them in relation to level of severity, scientific evidence,
time of onset, and potential clinical impact in adult and older
adult patients with diabetes mellitus 2 (DM2).
Methods
Study design and setting
This cross-sectional study was conducted in an outpatient cen-
ter specializing in DM, Arterial Hypertension and Obesity, at
the Hospital de Clínicas, University of Campinas, Brazil. The
service undertakes an average of 700 free attendances per year
for adults and older adult patients, as it is part of the Unified
Health System.
Sample selection and data collection
The consecutive sample was made up of 140 adult and older
adult patients with DM2, receiving drug treatment with at least
two medications, and who had been treated on an outpatient
basis for a minimum of 12 months in the service. Data collec-
tion took place between May and October 2012. For extrac-
tion of the data, patient medical records were consulted, and
an instrument was used which was made up of demographic-
clinical variables and those related to the drug treatment.
Classification of the potential DDI
The present study considers the potential drug-drug interactions
(PDDIs). This term refers to the possibility of a given medica-
tion altering the intensity of the pharmacological effect of an-
other medication used simultaneously by the patient [10–12].
Only the PDDI related to major those that were quite severe
were considered clinically significant due to the potential im-
pact on the morbidity or mortality of the patients. The analysis
of the PDDI was undertaken using the DRUG-REAX® system
(Truven Health Products, 2015), which allows the identifica-
tion of the PDDI according to severity, scientific evidence, time
of onset and provides additional information such as potential
clinical impact and clinical management [22].
The level of severity was categorized as follows: contrain-
dicated, concomitant drug use is not recommended; major,
interaction may be life-threatening and/or require medical in-
tervention to reduce or prevent serious adverse effects; mod-
erate, the interaction may result in aggravation of the patient’s
condition and/or require a change in the therapy; minor, the
interaction would result in limited clinical effects and could
include an increase in the frequency or severity of side effects
but should generally not require any change in therapy; and
unknown, interactions are unknown [22]. In terms of scientific
evidence, the PDDIs were categorized as follows: excellent,
controlled clinical studies have clearly established the exis-
tence of DDI; good, the documentation strongly suggests that
there is an interaction, but no controlled clinical studies are
available; fair, availability of documentation is poor, although
pharmacological considerations exist regarding the interac-
tion, or the documentation is good for a pharmacologically
similar drug; and unknown, there is no evidence of such in-
teractions [22]. For the time of onset, the PDDIs were classi-
fied as follows: rapid, onset expected within 24 h; delayed,
onset not expected to occur within the first 24 h; and not
specified, time not known [22].
Analysis of the data
The data collected were transferred to a Microsoft Excel
2010® Windows 8 spreadsheet, using double keying. The
medications were classified by the Anatomical-Therapeutic-
Chemical Classification—ATC, in level 1—main anatomical
group [20]. The description of the qualitative variables was
undertaken through the calculation of frequencies and percent-
ages, and for the quantitative variables, measures of central
tendency and dispersion were calculated. In order to study the
association and the variables of sex, age range, number of
drugs taken, body mass index (BMI) (normal, pre-obesity,
and obesity), number of comorbidities, time since diagnosis,
and HbA1c values with the variables of presence/absence of
PDDI, simple logistic regression models were applied [21]
and, subsequently, multiple models were constructed with
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the stepwise criteria for selecting variables. The HbA1c values
used in this study were based on a previous study [23], which
demonstrated that HbA1c values between 7 and 8 % contrib-
ute to lower risks of mortality in diabetic patients. The results
were presented through calculations of the raw and adjusted
odds ratios. For all the analyses, a level of significance equal
to 5 % was considered, and the SAS (Statistical Analysis
System) statistical software, version 9.2, was used.
Results
Clinical-demographic profile
Over a 6-month period, 140 patients with a diagnosis of DM
were included in this study. The distribution of these
sociodemographic and clinical characteristics is presented in
Table 1.
Therapeutic profile and potential drug interactions
The mean number of drugs used was 6.3 (SD 2.6). The ma-
jority of patients (79.3 %) were using five or more drugs. A
total of 75 active substances were prescribed, with 364 pairs of
PDDI being found: 39 (10.7 %) belonged to the group of
major severity PDDI, 300 (82.4 %) belonged to the group of
moderate severity PDDI, and 25 (6.9 %) to the group of minor
PDDI. Contraindicated PDDIs were not found.
Among the 140 individuals, 105 were exposed to at least
one PDDI, resulting in prevalence of 75.0 %. Among these
patients, more than half (63.2 %) were exposed to between
one and three PDDIs (mean of 2.6, SD 1.8). The prevalence of
patients exposed to major PDDI was 20.7 % (n = 29), the case
being that, in this group, 72.4 % were exposed to at least one
major PDDI, 20.6 % to two major PDDIs, and 7 % to three
major PDDIs. Table 2 presents the data referent to the 105
patients exposed to PDDI. In both the group of older adults
and the group of adults, the moderate PDDIs were the most
frequent (66.7 %), followed by the major PDDI (27.6 %).
Among the medications which contributed most to major
severity PDDI, 50.0 % belonged to group C (cardiovascular
system), followed by 17.8 % to group A (digestive system
and metabolism) and 17.8 % to group N (nervous system).
Simvastatin 30.8 %, captopril/enalapril 12.8 %, and oral
antidiabetics/insulin 12.8 % were the drugs which were most
involved in these events. In relation to the major PDDI, 86.9 %
of the scientific evidence was classified as either excellent or
good quality; 47.8%was classified as delayed, that is, the onset
was not expected to occur within the first 24 h (Table 3).
Statistically significant differences were not found in the
multiple models between the variable presence/absence of
PDDI with sex, age range, BMI, number of comorbidities,
time since diagnosis, and HbA1c. In both univariate and mul-
tiple analyses, the number of drugs prescribed was associated
with PDDI, with a growing risk among both patients who
were not using five or more drugs and those who were doing
so (OR = 10.46; CI 95 % 4.10–26.71) (Table 4).
Discussion
The patients in the present investigation used a number of
medications (6.3; SD 2.6) similar to that in other studies held
in a tertiary healthcare outpatient center which included pa-
tients with DM2 in their samples [24–27].
Approximately 79 % of the patients made use of five or
more medications. In the literature, the values for
polypharmacy varied from 25.2 to 96.7 % [8, 15, 24, 25, 27,
28]. It is believed that this variation referent to the number of
patients using five or more medications may be related to the
level of care (primary or tertiary), to the associated morbid-
ities, and to the study design.
In the present study, the prevalence of patients exposed to
PDDI was 75 %. Rates of PDDI varying from 52.2 to 93.3 %
have been described in patients receiving outpatient treatment
in various specialties, including DM2 [19, 24, 25, 27].
Table 1 Demographic-clinical characteristics of patients with diabetes
mellitus type 2, attended in a tertiary healthcare outpatient center
Demographic-clinical variables Number (%)
Sex
Female 75 53.6
Male 65 46.4
Age in years
Mean (SD) 60.5 (9.4) –
Individuals <60 years 67 47.9
Individuals ≥60 years 73 52.1
BMI
Mean (SD) 29.5 (6.1) –
Comorbidities
Systemic arterial hypertension 121 86.4
Dyslipidemia 93 66.4
Obesity 66 47.5
Peripheral vascular disease 38 27.3
Previous acute myocardial infarction 24 17.5
Angina 13 9.3
Cerebrovascular accident 06 4.3
HbA1C
Mean (SD) 8.6 (1.9) –
<7 33 23.6
≥7 and ≤8 31 22.1
>8 % 76 54.3
Fasting glycemia
Mean (SD) 166.3 (69.3) –
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In this study, the prevalence of patients exposed to major
severity PDDI was 20.7 %. This result is superior to the find-
ings of a Mexican study which presented a prevalence of
major PDDI of 3.8 %, in which only 29.5 % of the patients
were diabetics [25]. This fact may be associated with the pa-
tients’ differences in relation to the diagnoses and consequent-
ly, in relation to the drug treatment prescribed.
The prevalence of pairs of major severity PDDIwas 10.7%
in the present study, this result falling within the values (3.67–
17.6 %) present in other investigations with patients receiving
outpatient treatment, which included DM2 [19, 24, 26, 27].
The major PDDI are considered clinically relevant, as it is
important for health professionals to be aware of the risks
related to the PDDI, so that measures may be implemented
in order to ensure safe care for the patient.
The medications involved with the greatest frequency in
major severity PDDI were simvastatin, captopril/enalapril,
and oral antidiabetics/insulin, which is consistent with other
studies which presented these combinations [9, 15].More than
half of the participants (58.6 %) had SAH and dyslipidemia,
Table 2 Distribution of patients
with diabetes mellitus type 2
monitored in tertiary care, in
relation to exposure to potential
drug interactions, by severity
Severity Number (%) of patients exposed to potential drug interactionsa
Adults Older adults Total
Contraindicated – – 0 (0)
Major 11 (37.9) 18 (62.1) 29 (27.6)
Moderate 32 (45.7) 38 (54.3) 70 (66.7)
Minor 3 (50.0) 3 (50.0) 6 (5.7)
Total 46 (43.8) 59 (56.2) 105 (100.0)
a The patients exposed to more than one potential drug interaction were considered only once, that is, by the
interaction with the greatest relevance
Table 3 Frequency of pairs of clinically significant major severity potential drug interactions in prescriptions of patients with diabetes mellitus type 2
attended in a tertiary healthcare outpatient center
Drug A Drug B Frequency
(%)
Potential clinical impact Evidence Time
Simvastatin Amiodarone 10 (25.6) ↑ risk of rhabdomyolysis and myopathy E R
G RAmlodipine
Captopril Spironolactone 5 (12.8) Hyperkalemia G D
Enalapril
NPH insulin Norfloxacin 4 (10.3) Important glycemic alterations E R
Insulin R
Metformin
Glibenclamide
Clopidogrel Omeprazole 4 (10.3) ↓ clopidogrel efficacy and ↑ risk of thrombosis E R
NSAmlodipine
Simvastatin Warfarin 2 (5.1) ↑ risk of rhabdomyolysis and of bleeding E D
Captopril Losartan 2 (5.1) Hypotension, syncope, kidney failure E NS
Amiodarone Carvedilol 2 (5.1) Hypotension, bradycardia, and cardiac arrest E R
Propranolol
Digoxin Amiodarone 2 (5.1) Nausea, vomiting and cardiac arrhythmia E D
Spironolactone G
Carbamazepine Fluoxetine 2 (5.1) ↑ risk of toxicity of the carbamazepine G NS
Atenolol Diltiazem 1 (2.6) Hypotension, bradycardia, atrioventricular conduction disturbances G R
Atenolol Clonidine 1 (2.6) ↑ risk of sinus bradycardia F NS
Amitriptyline Fluoxetine 1 (2.6) Prolongation of the QT interval, torsades de pointes, cardiac arrest G NS
Metformin Topiramate 1 (2.6) ↑ risk of lactic acidosis F NS
Hydrochlorothiazide Lithium 1 (2.6) ↑ of the concentration of the lithium (weakness, tremors, excessive thirst and
confusion)
G NS
Allopurinol Enalapril 1 (2.6) Hypersensitivity reactions F R
↑ increase, ↓ decrease, F fair, G good, E excellent, R rapid, D delayed, NS not specified
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associatedwith DM2. This may explain the greater occurrence
of PDDI with cardiovascular system drugs, as well as with
medications for controlling dyslipidemia.
In general, the statins are used for preventing cardiac events
and are well established for patients with dyslipidemia [29];
accordingly, simvastatin is a medication which is widely pre-
scribed for the patient with DM2, given that dyslipidemia is a
frequently associated comorbidity. Combined with
amlodipine or amiodarone, there is an increase in the risk for
myopathy and rhabdomyolysis; the risk of rhabdomyolysis
and bleeding also increases with the use of warfarin [30–32].
In this way, these PDDIs represent a risk to health and conse-
quently require interventions from the multi-professional team
for preventing serious adverse effects. These patients must be
monitored and guided in relation to signs and symptoms of the
disease.
The risk for hyperkalemia occurred with the combined use
of captopril/enalapril with spirinolactone in 12.8 % of the
PDDI. This phenomenon is usually asymptomatic, and the
greatest risk is the occurrence of arrhythmias. One study indi-
cated that the combination of angiotensin-converting enzyme
inhibitors with spironolactone gave rise to hyperkalemia, pos-
ing serious risks to the patients; 76 % of the patients presented
electrocardiographic changes compatible with hyperkalemia
(T tenting, QRS widening, or PR prolongation), with two
patients dying in the emergency room [33].
One study revealed that the combination of these drugs was
also associated with a significant increase in the risk of pa-
tients being transferred to the intensive care unit (ICU) or
dying. The risk of death after 2 days from the detection of
hyperkalemia was 5.3 times greater than in patients who were
not exposed to PDDI, which led to this adverse event [34].
The combination, therefore, must be carefully evaluated with
regard to the risk and benefit for each patient.
Other important combinations found in this study were for
norfloxacin with insulin or oral antidiabetics (10.3 %). Ac-
cording to the literature, the main effect of combining these
drugs is severe hypoglycemia [35, 36]. It is important to em-
phasize that the patient who maintains rigor in metabolic con-
trol already presents a risk for hypoglycemia and, associated
with the combination of these drugs, the risks increase and
may expose the patient to risks of death.
Table 4 Factors associated with the potential drug interactions in patients with diabetes mellitus type 2 attended in a tertiary healthcare outpatient
center
Variable PDDI Raw odds ratio (C.I. 95 %) p value Adjusted odds ratio (C.I. 95 %)* p value
No Yes
n % n %
Sex
Male 14 21.54 51 78.46 1.00 (ref) 0.3797
Female 21 28.00 54 72.00 0.71 (0.33; 1.54)
Age range (years)
<60 21 31.34 46 68.66 1.00 (ref) 0.0994
≥60 14 19.18 59 80.82 1.92 (0.88; 4.19)
BMI
Normal 12 37.50 20 62.50 1.00 (ref) 0.1385
Pre-obesity 12 25.00 36 75.00 1.75 (0.66; 4.07)
Obesity 11 18.33 49 81.67 2.67 (1.00; 7.05)
No. of drugs
<5 19 65.52 10 34.48 1.00 (ref) < 0.0001 1.00 (ref) <0.0001*
≥5 16 14.41 95 85.59 11.28 (4.45; 28.62) 10.46 (4.10; 26.71)
No. of comorbidities
≤2 25 35.21 46 64.79 1.00 (ref) 0.0058
>2 10 14.49 59 85.51 3.21 (1.40; 7.34)
Time since diagnosis
≤60 months 9 21.95 32 78.05 1.00 (ref) 0.5924
>60 months 26 26.26 73 73.74 0.79 (0.33; 1.87)
HbA1c (%)
<7 7 21.2235 26 78.78 1.00 (ref) 0.6389
≥7 and ≤8 7 22.58 24 77.42 0.82 (0.24; 2.80)
>8 21 27.63 55 72.37 0.63 (0.23; 1.75)
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The combination of clopidogrel with omeprazole or
amlodipine was also among the most common in this study
(10.3 %). The USA’s Food and Drug Administration (FDA)
issued an alert regarding the interaction of clopidogrel with
omeprazole [37]. Omeprazole reduces the antiplatelet effect of
clopidogrel by approximately 50.0 %. However, it seems that
omeprazole is rapidly eliminated, and the PDDI may be atten-
uated when the clopidogrel and the omeprazole are adminis-
tered with an interval of 12 h. In some studies, the concomitant
use of calcium channel blockers and clopidogrel was associ-
ated with a reduction of the action of the clopidogrel [38, 39].
In other studies, however, this hypothesis was not confirmed,
and in these cases, there is no evidence that calcium channel
blockers may reduce the efficacy of the treatment using
clopidogrel [40, 41]. For this, it is necessary to undertake
studies which better seek scientific evidence.
The use of five or more drugs was significantly associated
with PDDI. Polypharmacy is a factor which is well document-
ed in the literature as a factor associated with PDDI, indepen-
dent of the disease investigated, country or place of care, and
health treatment [8, 9, 12–18]. The polypharmacy recorded in
this study is expected for this population, given that these
individuals present an increased risk for cardiovascular dis-
eases, such as SAH, dyslipidemias, and abnormalities related
to coagulation. The higher the number of comorbidities, the
greater the chances of co-administration of various drugs for
the control of DM and its associated comorbidities.
The present study’s results confirm the risk to the safety of
patients with chronic diseases who are subjected to
polypharmacy. The professional team needs to exercise con-
tinuous surveillance in relation to identifying signs/symptoms
and possible alterations in laboratory examinations which re-
sult from PDDI and to review drug treatment so as to propose
changes when possible. Furthermore, the professional must
advise patients and their family members with the aim of
reinforcing the early identification and treatment of these pos-
sible clinical implications. It falls to the health system to im-
plement warning systems in the electronic prescriptions, with
the aim of detecting and preventing prescriptions with prob-
lems, as well as providing databases on PDDI which allow
PDDI to be tracked in real time. The use of warning systems
for categorizing PDDI by severity, in certain care scenarios,
has improved the acceptance of the clinical recommendations,
such that specific medications should not be prescribed simul-
taneously [42].
Among this study’s limitations, one finds the selection of
the consecutive sample, which may prejudice its external va-
lidity. The PDDIs were established through the evaluation of
the medical prescriptions of patients treated on an outpatient
basis and were not compared with the actual clinical impact
caused to the patient, which indicates a field for future inves-
tigations. On the other hand, this study, undertaken with dia-
betic patients, appears to be one of the first to investigate
PDDI in this population, which contributes to shedding light
on those PDDIs which are clinically significant, and provides
data for assisting in developing warning systems for treatment
of persons with diabetes, this being a group with greater vul-
nerability, due to the presence of comorbidities, the increase of
possibilities of complications, and the use of complex
polypharmacy.
Conclusion
Diabetic patients were exposed to clinically significant PDDI,
the case being that polypharmacy increased the chances for
PDDI. The most frequent potential clinical impacts were rhab-
domyolysis, hyperkalemia, and important glycemic alter-
ations. It is important for health professionals to know the
risks related to the PDDI, so that measures may be implement-
ed in order to ensure safe care for the patient. Changing the
therapeutic scheme must be discussed within the multi-
professional team and undertaken where possible.
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